During the last decade the therapeutic landscape of NSCLC has been profoundly changed with the discovery of Epidermal Growth Factor Receptor (EGFR) mutations and the clinical demonstration of superiority of EGFR Tyrosine Kinase Inhibitors (TKIs) over chemotherapy in molecularly selected NSCLCs [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.